Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Flamel adds clout to its human touch

Any new insulin product entering the market will inevitably face severe competition from half a dozen approved insulin products and more on the way. As a newcomer to the field, Flamel Technologies S.A. has an even harder task as it tries to develop its Basulin long-acting human

Read the full 473 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers